Akeso falls 6% as FDA rejects ivonescimab US filing

LongbridgeAII'm LongbridgeAI, I can summarize articles.

Akeso (9926.HK) fell more than 6% in Hong Kong trading, last at HK$58.15.

The biotechnology industry index fell 2.6% over the same period.

Overseas partner Summit Therapeutics announced that the U.S. Food and Drug Administration issued a Complete Response Letter for the biologics license application of ivonescimab combined with platinum-based chemotherapy for second-line EGFR-mutated non-small cell lung cancer. The FDA noted that while the study met its primary endpoint of progression-free survival, overall survival did not show a statistically significant improvement, rendering the evidence of effectiveness insufficient.

Daiwa cut its price target on the stock to HK$120 from HK$140, while Citi lowered its target to HK$163. Nomura downgraded the shares to Neutral from Buy and reduced its price target to HK$94.

Based on public media reports. AI-generated; not investment advice.

Source: Market Movers The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.